Anaphylaxis News and Research RSS Feed - Anaphylaxis News and Research

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.
Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Starpharma receives approvals to commence phase 1 human clinical trial for DEP-Docetaxel

Starpharma today announced that it has received the necessary approvals to commence a phase 1 human clinical trial for its dendrimer-enhanced docetaxel (Taxotere®) chemotherapeutic product, referred to as DEP™-Docetaxel. [More]
Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma. [More]
Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Shield Therapeutics reports positive top-line data from pivotal Phase 3 programme of ST10

Shield Therapeutics, an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces strongly positive top-line data from the pivotal Phase 3 programme of ST10 for the treatment of iron deficiency anaemia in inflammatory bowel disease. [More]
FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors. [More]
GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

GlaxoSmithKline plc announced today that a peer-reviewed study issued online by the New England Journal of Medicine has reported that GSK's FluLaval® Quadrivalent reduced flu cases among children ages 3-8 by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%. [More]
Crealta to acquire all assets of Savient Pharmaceuticals

Crealta to acquire all assets of Savient Pharmaceuticals

Savient Pharmaceuticals, Inc. ("Savient") announced that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds of approximately $120.4 million. [More]
Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc. [More]
People with food allergy more likely to be murdered than to die from severe reaction

People with food allergy more likely to be murdered than to die from severe reaction

A person with a food allergy is more likely to be murdered than to die from a severe reaction, according to a new study. [More]
Intelliject to be recognized with George DiDomizio Industry Award

Intelliject to be recognized with George DiDomizio Industry Award

The Institute for Safe Medication Practices has announced that this year's George DiDomizio Industry Award is being presented to Intelliject, Inc. for pioneering advances in drug/device combination products with the Auvi-Q epinephrine auto-injector (also known as Allerject™ in Canada). Auvi-Q is the first auto-injector with audio as well as visual cues for the emergency treatment of life-threatening allergic reactions. [More]
Flublok influenza vaccine for the 2013-14 season now available

Flublok influenza vaccine for the 2013-14 season now available

Protein Sciences Corporation, the manufacturer of Flublok, the new, pure influenza vaccine containing no egg proteins, influenza virus, preservatives (e.g., thimerosal), antibiotics, gelatin or latex, announced today that doses for the 2013-14 season have been released by the FDA and are now available. [More]
Life-saving bone marrow transplants may also cure peanut allergies

Life-saving bone marrow transplants may also cure peanut allergies

Not only can bone marrow transplants be life-saving for children with acute lymphocytic leukemia, they may also cure peanut allergies. According to research presented during the American College of Allergy, Asthma and Immunology's Annual Scientific Meeting, a 10-year-old boy no longer had a peanut allergy after undergoing a bone marrow transplant. [More]
Oral allergy syndrome sufferers with hypertension may be at increased risk for severe reaction

Oral allergy syndrome sufferers with hypertension may be at increased risk for severe reaction

​Oral allergy syndrome sufferers that take high blood pressure medications may experience extreme facial swelling and difficulty breathing the next time they bite into a juicy apple. [More]
Anaphylaxis due to shrimp allergy is less than 8% in children

Anaphylaxis due to shrimp allergy is less than 8% in children

Anaphylaxis is a severe allergic reaction that can be life-threatening. Shellfish is the third most common food allergy to cause anaphylaxis. [More]
People with gelatin allergy can have reaction from flu vaccinations

People with gelatin allergy can have reaction from flu vaccinations

Do marshmallows make your tongue swell? Gummy bears make you itchy? If you've answered yes and are allergic to gelatin, you will want to take some precautions when getting the flu shot. [More]
FDA approves Prior Approval Supplement for EMBEDA Extended Release Capsules CII

FDA approves Prior Approval Supplement for EMBEDA Extended Release Capsules CII

Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved a Prior Approval Supplement for EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII. [More]

Severe allergies in young people: an interview with Lynne Regent, CEO of Anaphylaxis Campaign

Around one third of the UK population – approximately 19 million people – will develop an allergy at some time in their lives. A significant proportion of these – around a million people – suffer severe symptoms. [More]
FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

FDA accepts, files Genentech's sBLA for subcutaneous use of Xolair in people with CIU

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted and filed the company's supplemental Biologics License Application for subcutaneous use of Xolair (omalizumab) in people with Chronic Idiopathic Urticaria who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses. [More]
Halloween parties can heighten danger for kids with food allergies

Halloween parties can heighten danger for kids with food allergies

The scary reality is that food allergies are becoming more and more common in the United States. In the past 10 years there has been an 18 percent increase in children with food allergies. [More]
Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen today announced that it will present data from several romosozumab and Prolia® (denosumab) studies at the American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting in Baltimore from Oct. 4-7, 2013. [More]
New research shows no increased danger for egg allergic children who take flu shots

New research shows no increased danger for egg allergic children who take flu shots

All children should have flu shots, even if they have an egg allergy, and it's now safe to get them without special precautions. This finding is from the latest update on the safety of the flu vaccine for allergic patients, published in the October issue of the Annals of Allergy, Asthma and Immunology, the official journal of the American College of Allergy, Asthma and Immunology. [More]